Journal of Hematology & Thromboembolic Diseases
Open Access

The Link Between Hematology Parameters and Autoimmune Thyroid Diseases

Claudia Rehnberg^{* *}Correspondence: Claudia Rehnberg, Department of Hemostasis and Thrombosis, University of Sao Paulo, Sao Paulo, Brazil, Email:

Author info »

Description

Autoimmune Thyroid Diseases (AITDs), including Hashimoto’s thyroiditis and Graves’ disease, represent a significant portion of thyroid disorders with complex pathophysiological mechanisms. AITDs are characterized by immune system dysfunction, where the body's immune system mistakenly targets thyroid cells, leading to either hypo- or hyperthyroidism. This autoimmune attack on thyroid cells often results in various systemic manifestations and abnormalities, particularly in hematological parameters. Hematological changes in autoimmune thyroid diseases have been widely studied in clinical settings, revealing distinct alterations in blood cell counts, clotting factors, and other markers of inflammation. Understanding the link between hematology parameters and autoimmune thyroid diseases is crucial for better patient management, early diagnosis, and predicting disease outcomes.

Autoimmune Thyroid Diseases: An Overview

AITDs encompass two major conditions in Hashimoto’s thyroiditis and Graves’ disease. Both conditions involve the immune system attacking thyroid cells, but the clinical manifestations and outcomes differ.

Hashimoto’s Thyroiditis: This is the most common cause of hypothyroidism worldwide. In Hashimoto's thyroiditis, the immune system produces antibodies against Thyroid Peroxidase (TPO) and Thyroglobulin (TG), leading to thyroid cell destruction. Patients with Hashimoto's may present with fatigue, weight gain, depression, and other hypothyroid symptoms.

Graves’ Disease: In contrast, Graves' disease is the most common cause of hyperthyroidism. It occurs when the immune system produces stimulating antibodies against the Thyroid-Stimulating Hormone Receptor (TSHR), leading to excessive thyroid hormone production. Symptoms of hyperthyroidism include weight loss, palpitations, tremors, and anxiety.

Hematology Parameters in Autoimmune Thyroid Diseases

The most commonly observed hematological alterations include changes in the number and function of blood cells, as well as abnormalities in coagulation markers.

Anemia: One of the most frequent hematologic abnormalities in AITDs is anemia. The mechanism behind anemia in autoimmune thyroid diseases is multifactorial. Hypothyroidism, as seen in Hashimoto’s thyroiditis, can lead to Anemia of Chronic Disease (ACD), characterized by low serum iron levels and low reticulocyte counts. Conversely, in hyperthyroidism, there is an increased metabolic demand that may also impair erythropoiesis, contributing to mild anemia in some cases. However, anemia in Graves’ disease may be less frequent than in Hashimoto’s thyroiditis and is typically associated with other comorbidities, such as autoimmune hemolytic anemia or iron deficiency due to gastrointestinal losses.

Leukocyte alterations: Hematologic analysis often reveals leukocytosis or leukopenia in patients with AITDs. Elevated White Blood Cell (WBC) counts are more commonly observed in Graves' disease due to the heightened inflammatory state and autoimmune activation. In some patients, this increase in WBCs can be due to concurrent infections or an exaggerated inflammatory response to thyroid hormone excess.

Thrombocytopenia and thrombocytosis: Alterations in platelet counts are another significant hematologic finding in AITDs. Thrombocytopenia (low platelet count) has been observed in patients with Hashimoto’s thyroiditis and is often linked to the presence of autoimmune antibodies against platelets or bone marrow suppression.

Coagulation factors: Changes in coagulation markers are another important aspect of hematological findings in AITDs. Studies have shown that patients with Graves’ disease tend to have procoagulant states due to the increased levels of thyroid hormones, which enhance the synthesis of clotting factors, such as fibrinogen, prothrombin, and factor VIII. This elevated clotting activity can increase the risk of thrombosis and cardiovascular complications.

Conclusion

In summary, autoimmune thyroid diseases significantly impact hematology parameters through complex mechanisms involving autoimmune dysregulation, thyroid hormone imbalances, and systemic inflammation. Anemia, leukocyte alterations, thrombocytosis, and coagulation abnormalities are commonly observed in patients with these disorders, reflecting the broader systemic effects of thyroid dysfunction. Clinicians should remain vigilant in monitoring these parameters to optimize patient care, improve outcomes, and prevent complications associated with AITDs.